JPMorgan Starts ConforMIS (CFMS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
UPDATE: Oppenheimer Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:40 AM EDT(Updated - July 27, 2015 9:12 AM EDT)
Oppenheimer initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating and a price target of $26.
Analyst Steven Lichtman said, "CFMS's unique iFit technology provides custom implants designed to match the individual anatomy of a patient undergoing total... More
Wells Fargo Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:38 AM EDTWells Fargo initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating.
For an analyst ratings summary and ratings history on ConforMIS click here. For more ratings news on ConforMIS click here.
Shares of ConforMIS closed at $22.12 yesterday.
... MoreUPDATE: Canaccord Genuity Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:37 AM EDT(Updated - July 27, 2015 8:47 AM EDT)
Canaccord Genuity initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.00.
Analyst William J. Plovanic said, "We believe ConforMIS is a disruptive technology in the multi-billion dollar global orthopedic implant market.... More
Deutsche Bank Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:36 AM EDTDeutsche Bank initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.
Analyst Kristen Stewart said, "ConforMIS is an orthopedic manufacturer of fully customized implants utilizing its iFit technology--iFit design, iFit printing (3D printing), and iFit just-in-time... More
